Aurelia Zimmerli Matteo Monti Craig Fenwick Isabella Eckerle Catherine Beigelman-Aubry Céline Pellaton Katia Jaton Dominique Dumas Gian-Marco Stamm Laura Infanti Heidrun Andreu-Ullrich Daphné Germann Marie Mean Peter Vollenweider Raphael Stadelmann Maura Prella Denis Comte Benoit Guery David Gachoud Nathalie Rufer
10.3389/fimmu.2021.613502
Front Immunol
2021 Apr 21;12:613502.
b-cell depletion chronic sars-cov-2 infection convalescent plasma therapy neutralizing antibodies severe immunosuppression viral clearance
CC BY
https://pubmed.ncbi.nlm.nih.gov/33968017/
Antibodies, Neutralizing / blood Antibodies, Viral / blood COVID-19 / immunology COVID-19 / therapy COVID-19 Drug Treatment
Antibodies, Neutralizing / blood Antibodies, Viral / blood COVID-19 / immunology COVID-19 / therapy COVID-19 Drug Treatment Case Reports Research Support, Non-U.S. Gov't Aged Antibodies, Neutralizing / administration & dosage Antibodies, Viral / administration & dosage Antineoplastic Agents, Alkylating / therapeutic use Antineoplastic Agents, Immunological / therapeutic use Bendamustine Hydrochloride / therapeutic use COVID-19 Serotherapy Diabetes Mellitus, Type 2 / complications Humans Immunization, Passive / methods Immunoglobulin A / blood Immunoglobulin G / blood Immunoglobulin M / blood Immunosuppression Therapy Leukemia, Lymphoid / complications Leukemia, Lymphoid / drug therapy Male Rituximab / therapeutic use SARS-CoV-2 / drug effects SARS-CoV-2 / immunology Treatment Outcome Antibodies, Neutralizing Antibodies, Viral Antineoplastic Agents, Alkylating Antineoplastic Agents, Immunological Immunoglobulin A Immunoglobulin G Immunoglobulin M Rituximab Bendamustine Hydrochloride
PMC8097002
33968017
Case Report: Stepwise Anti-Inflammatory and Anti-SARS-CoV-2 Effects Following Convalescent Plasma Therapy With Full Clinical Recovery
2021